Clinical choices of antibiotics: Judging judicious use

American Journal of Managed Care

Volumn 6, Issue 23 SUPPL., 2000, Pages

  Steinberg, I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLARITHROMYCIN; DOXYCYCLINE; GATIFLOXACIN; LORACARBEF; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; CAREGIVER; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG CHOICE; DRUG COST; DRUG FORMULATION; DRUG MISUSE; DRUG USE; HUMAN; MEDICAL AUDIT; PATIENT EDUCATION; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION REVIEW; HEALTH SERVICES MISUSE; HUMANS; OTITIS MEDIA; PATIENT EDUCATION; PHYSICIAN'S PRACTICE PATTERNS; RESPIRATORY TRACT INFECTIONS; UNITED STATES;

EID: 0034519346     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. The continuing causes and costs of antimicrobial resistance
2. Outpatient visits for infectious diseases in the United States, 1980 through 1996
3. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians
4. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis
5. Antibiotics in acute bronchitis: A meta-analysis
6. What's in a name? Public knowledge, attitudes, and experiences with antibiotic use for acute bronchitis
7. Antibiotic prescribing for Canadian pre-school children: Evidence of overprescribing for viral respiratory infections
8. Antibiotic prescribing by pediatricians for respiratory tract infection in children
9. Antimicrobial use for pediatric upper respiratory infections: Reported practice, actual practice, and parent beliefs
10. Characteristics and experiences of parents and adults who want antibiotics for cold symptoms
11. Antibiotics for upper respiratory tract infections. Follow-up utilization and antibiotic use
12. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance
13. Provider and community education decreases antimicrobial use and carriage of penicillin-resistant Streptococcus pneumoniae in rural Alaska communities
14. Decreasing antibiotic use in ambulatory practice: Impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults
15. The pharmacist's role in promoting optimal antimicrobial use
16. U.S. counties with higher rates of antibiotic use have significantly higher proportions of β-lactam and macrolide nonsusceptible S. pneumoniae antimicrobial resistance
17. Trends in antibiotic resistance of respiratory pathogens: An analysis and commentary on a collaborative surveillance study
18. Trends in antimicrobial drug prescribing among office-based physicians in the United States
19. Outcomes among cephalosporins: A real-world retrospective analysis of antibiotic switch rates in 630,000 patients
20. Management of otitis media among children in a large health insurance plan
21. Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae
22. The emergence of mefE in macrolide-resistant Streptococcus pneumoniae: A population-based assessment
23. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study
24. Susceptibility of Streptococcus pneumoniae to macrolides in immunocompetent adults with community acquired pneumonia
25. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers
26. Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects
27. Checkerboard and time-kill assays for determining synergy of clarithromycin and 14-hydroxyclarithromycin against penicillin-intermediate, -resistant, and -highly resistant Streptococcus pneumoniae
28. Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance
29. Comparison of clarithromycin and loracarbef in the treatment of secondary bacterial infections of acute bronchitis
30. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis
31. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society
32. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia
33. Once daily 400 mg oral gatifloxacin vs twice daily 500 mg clarithromycin in the treatment of community-acquired pneumonia
34. Clarithomycin Pharyngitis Study Group
35. Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin v in the treatment of acute streptococcal pharyngitis in children: Results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group
36. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media
37. Correlation of clarithromycin treatment outcome with MIC for Haemophilus influenzae in secondary bacterial infection of acute bronchitis
38. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection
39. Macrolides, asthma, inflammation, and infection
40. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
41. Practice guidelines for the management of community-acquired pneumonia in adults
42. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
43. Pharmacokinetics and safety of a once-daily clarithromycin formulation
44. In vitro comparative dynamics of modified-release clarithromycin and of azithromycin
45. Efficacy and safety of once-daily and twice-daily clarithromycin formulations in the treatment of acute exacerbations of chronic bronchitis
46. Safety and efficacy of clarithromycin extended release compared to clarithromycin immediate release in the treatment of acute maxillary sinusitis
47. Safety and efficacy comparison of clarithromycin extended release with trovafloxacin in community-acquired pneumonia. 38th IDSA Meeting
48. In vitro comparative dynamics of modified-release clarithromycin and of azithromycin
49. Safety and efficacy comparison of clarithromycin extended-release with levofloxacin in community-acquired pneumonia